About ADRX
- Industry:
- Exchange:
- Country:
Frequently Asked Questions
What is the 52-week range for ADRX?
The 52-week high is $23.21 and the 52-week low is $18.5.
What is the P/E ratio for ADRX?
The P/E ratio data is currently unavailable.
What is the dividend yield for ADRX?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
ROE data is currently unavailable.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
P/B ratio data is currently unavailable.
Latest ADRX News
ADARx Pharmaceuticals Announces the Closing of Full Exercise of Underwriters’ Option to Purchase Additional Shares Granted in Its Initial Public Offering
SAN DIEGO, Oct. 01, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx) (Nasdaq: ADRX), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today that, in connection with its upsized initial public offering of its common stock, the underwriters have fully exercised their option to purchase an additional 3,937,500 shares of ADARx’s common stock at a price to the public of $17.00 per share. The issuance of the additional shares closed on Oc
ADARx Pharmaceuticals (ADRX) Moved Higher, But What Is Drawing Attention?
ADARx Pharmaceuticals (ADRX) has just completed a US$446.25 million IPO at US$17 per share, placing the RNA-focused biotech at roughly US$2.1 billion in market value. The first sessions post listing have been active for ADARx Pharmaceuticals, with the latest share price at US$19.35 giving a 1 day share price return of 13.82% and the same 13.82% share price return year to date. This hints at early momentum as investors weigh the freshly raised capital against the risks and timelines of its...
U.S. IPO Weekly Recap: Postponed Deals Put Damper On Fall IPO Market
One IPO and two SPACs debuted this week, although more deals were originally on the calendar. Read more here.
ADARx Pharmaceuticals Announces Pricing of Upsized $446.3 Million Initial Public Offering
SAN DIEGO, Sept. 24, 2026 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation siRNA therapeutics, announced today the pricing of its upsized initial public offering of 26,250,000 shares of common stock at a price to the public of $17.00 per share. All of the shares of common stock are being offered by ADARx. The gross proceeds to ADARx from the offering, before deducting underwriting discounts and commissions and offerin
ADARx Pharmaceuticals Seeks IPO On Strong Collaboration Deal With AbbVie
ADARx Pharmaceuticalsâ IPO aims to fund its RNA therapy pipeline; see Phase 3 Onvuzosiran timeline and AbbVie deal validationâread before investing.
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | -198,019 | - | - |
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | -1,953,773 | - | - |
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | -1,802,885 | - | - |
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | -600,962 | - | - |
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | -1,304,883 | - | - |
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | -3,907,547 | - | - |
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | +592,593 | $17 | $10,074,081 |
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | +169,001 | - | - |
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | +1,667,468 | - | - |
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | +414,814 | $17 | $7,051,838 |
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | +1,538,691 | - | - |
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | +592,593 | $17 | $10,074,081 |
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | +512,897 | - | - |
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | +1,113,666 | - | - |
| 2026-09-28 | SR ONE CAPITAL MANAGEMENT, LLC | +3,334,938 | - | - |
| 2026-09-28 | LAV Biosciences Fund V, L.P. | -360,577 | - | - |
| 2026-09-28 | LAV Biosciences Fund V, L.P. | -360,577 | - | - |
| 2026-09-28 | LAV Biosciences Fund V, L.P. | -180,288 | - | - |
| 2026-09-28 | LAV Biosciences Fund V, L.P. | -601,161 | - | - |
| 2026-09-28 | LAV Biosciences Fund V, L.P. | -1,953,774 | - | - |
| 2026-09-28 | LAV Biosciences Fund V, L.P. | -10,438,412 | - | - |
| 2026-09-28 | LAV Biosciences Fund V, L.P. | +307,738 | - | - |
| 2026-09-28 | LAV Biosciences Fund V, L.P. | +307,738 | - | - |
| 2026-09-28 | LAV Biosciences Fund V, L.P. | +153,868 | - | - |
| 2026-09-28 | LAV Biosciences Fund V, L.P. | +513,067 | - | - |
| 2026-09-28 | LAV Biosciences Fund V, L.P. | +1,667,469 | - | - |
| 2026-09-28 | LAV Biosciences Fund V, L.P. | +8,908,775 | - | - |
| 2026-09-28 | George Simeon | -198,019 | - | - |
| 2026-09-28 | George Simeon | -1,953,773 | - | - |
| 2026-09-28 | George Simeon | -1,802,885 | - | - |
| 2026-09-28 | George Simeon | -600,962 | - | - |
| 2026-09-28 | George Simeon | -1,304,883 | - | - |
| 2026-09-28 | George Simeon | -3,907,547 | - | - |
| 2026-09-28 | George Simeon | +592,593 | $17 | $10,074,081 |
| 2026-09-28 | George Simeon | +169,001 | - | - |
| 2026-09-28 | George Simeon | +1,667,468 | - | - |
| 2026-09-28 | George Simeon | +414,814 | $17 | $7,051,838 |
| 2026-09-28 | George Simeon | +1,538,691 | - | - |
| 2026-09-28 | George Simeon | +592,593 | $17 | $10,074,081 |
| 2026-09-28 | George Simeon | +512,897 | - | - |
| 2026-09-28 | George Simeon | +1,113,666 | - | - |
| 2026-09-28 | George Simeon | +3,334,938 | - | - |
| 2026-09-24 | MacLeod Alan Robert | +170,692 | - | - |
| 2026-09-24 | Zhu Rui (NMN) | +512,076 | - | - |
| 2026-09-24 | Ackles Robert William | +85,346 | - | - |
| 2026-09-24 | Fisk Ryan | +170,692 | - | - |
| 2026-09-24 | Li Zhen | +1,024,152 | - | - |